MiMedx falls on delayed earnings filing due to internal audit

Regenerative medicines company MiMedx Group Inc. (NASDAQ:MDXG) fell $5.72 (40%) to $8.75 on Tuesday after announcing it will delay the release of its fourth quarter and fiscal-year 2017 financial results as the company conducts an internal investigation into “current and prior-period matters relating to allegations regarding certain sales and distribution practices.” ...